These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21325856)

  • 1. Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis.
    Carmona O; Masuet C; Alía P; Moral E; Alonso-Magdalena L; Casado V; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2011; 65(3):132-7. PubMed ID: 21325856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
    Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
    Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S
    Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers.
    Burwick RM; Ramsay PP; Haines JL; Hauser SL; Oksenberg JR; Pericak-Vance MA; Schmidt S; Compston A; Sawcer S; Cittadella R; Savettieri G; Quattrone A; Polman CH; Uitdehaag BM; Zwemmer JN; Hawkins CP; Ollier WE; Weatherby S; Enzinger C; Fazekas F; Schmidt H; Schmidt R; Hillert J; Masterman T; Hogh P; Niino M; Kikuchi S; Maciel P; Santos M; Rio ME; Kwiecinski H; Zakrzewska-Pniewska B; Evangelou N; Palace J; Barcellos LF
    Neurology; 2006 May; 66(9):1373-83. PubMed ID: 16682670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of APOE genetic polymorphism with susceptibility to multiple sclerosis and its clinical phenotypes in Kuwaiti Arab subjects.
    Al-Shammri S; Fatania H; Al-Radwan R; Akanji AO
    Clin Chim Acta; 2005 Jan; 351(1-2):203-7. PubMed ID: 15563891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Apolipoprotein E polymorphism as a predictor of progression of multiple sclerosis].
    Guerrero AL; Bueno V; Hernández MT; Martín-Serradilla JI; Carrasco E; Cuadrado I
    Neurologia; 2003 Apr; 18(3):146-8. PubMed ID: 12677480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The absence of a relation between apolipoprotein E genotypes and the severity of multiple sclerosis in Mexican patients].
    Corona T; Guerrero-Camacho JL; Alonso-Vilatela ME; Flores-Rivera Jde J
    Rev Neurol; 2010 Jan 1-15; 50(1):19-22. PubMed ID: 20073019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta for multiple sclerosis: Long-term benefits?
    Rudick RA; Cutter G
    Ann Neurol; 2007 Apr; 61(4):283-5. PubMed ID: 17444503
    [No Abstract]   [Full Text] [Related]  

  • 9. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy.
    van der Walt A; Stankovich J; Bahlo M; Taylor BV; van der Mei IA; Foote SJ; Kilpatrick TJ; Rubio JP; Butzkueven H
    Neurology; 2009 Sep; 73(13):1018-25. PubMed ID: 19786693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis.
    Portaccio E; Zipoli V; Goretti B; Hakiki B; Nacmias B; Siracusa G; Sorbi S; Amato MP
    Acta Neurol Scand; 2009 Dec; 120(6):439-41. PubMed ID: 19804477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.
    Warabi Y; Matsumoto Y; Hayashi H
    J Neurol Sci; 2007 Jan; 252(1):57-61. PubMed ID: 17125797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation of a gene for multiple sclerosis (MS) to chromosome region 19q13.3.
    Lucotte GL;
    Genet Couns; 2002; 13(2):133-8. PubMed ID: 12150212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
    Lanzillo R; Prinster A; Scarano V; Liuzzi R; Coppola G; Florio C; Salvatore E; Schiavone V; Brunetti A; Muto M; Orefice G; Alfano B; Bonavita V; Brescia Morra V
    J Neurol Sci; 2006 Jun; 245(1-2):141-5. PubMed ID: 16626758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA class II and response to interferon-beta in multiple sclerosis.
    Fernández O; Fernández V; Mayorga C; Guerrero M; León A; Tamayo JA; Alonso A; Romero F; Leyva L; Alonso A; Luque G; de Ramón E
    Acta Neurol Scand; 2005 Dec; 112(6):391-4. PubMed ID: 16281922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No effect of APOE and PVRL2 on the clinical outcome of multiple sclerosis.
    Ramagopalan SV; Deluca GC; Morrison KM; Herrera BM; Dyment DA; Orton S; Bihoreau MT; Degenhardt A; Pugliatti M; Sadovnick AD; Sotgiu S; Ebers GC
    J Neuroimmunol; 2007 May; 186(1-2):156-60. PubMed ID: 17376543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new treatment era in multiple sclerosis: clinical applications of new concepts.
    Edan G; Leray E
    J Neurol Sci; 2011 Jul; 306(1-2):170-2. PubMed ID: 20951999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment.
    Alvarez-Lafuente R; Blanco-Kelly F; Garcia-Montojo M; Martínez A; De Las Heras V; Dominguez-Mozo MI; Bartolome M; Garcia-Martinez A; De la Concha EG; Urcelay E; Arroyo R
    Mult Scler; 2011 May; 17(5):513-20. PubMed ID: 21177319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
    Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
    J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
    Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.